Ten-year outcome of subthalamic stimulation in Parkinson disease: A blinded evaluation

Archives of Neurology

Volumn 68, Issue 12, 2011, Pages 1550-1556

  Castrioto, Anna ^a,b   Lozano, Andres M ^b   Poon, Yu Yan ^b   Lang, Anthony E ^b   Fallis, Melanie ^b   Moro, Elena ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; APRAXIA; ARTICLE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DEVICE INFECTION; DEVICE REMOVAL; DRUG RESPONSE; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; IMPULSE CONTROL DISORDER; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS; SUICIDE ATTEMPT; THERAPY EFFECT; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; WEIGHT REDUCTION;

AGED; DEEP BRAIN STIMULATION; DYSKINESIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SINGLE-BLIND METHOD; SUBTHALAMIC NUCLEUS; TIME FACTORS; TREATMENT OUTCOME; VIDEO RECORDING;

EID: 83455225213     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.182     Document Type: Article

References (22)

1. Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345(8942):91-95.
2. Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology. 1998;51 (3):850-855. (Pubitemid 28449271)
3. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology. 1999;53(1):85-90. (Pubitemid 29329653)
4. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925-1934. (Pubitemid 37409709)
5. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005; 128(pt 10):2240-2249. (Pubitemid 41407964)
6. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010; 25(5):578-586.
7. Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord. 2007; 22(7):990-997. (Pubitemid 46999296)
8. Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain. 2010;133 (9):2664-2676.
9. Deuschl G, Schade-Brittinger C, Krack P, et al. German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908. (Pubitemid 44315982)
10. Weaver FM, Follett K, Stern M, et al. CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
11. Williams A, Gill S, Varma T, et al.; PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581-591.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
13. Defer GL, Widner H, Marié RM, Reaposmy P, Levivier M. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov Disord. 1999;14(4):572-584. (Pubitemid 30011449)
14. Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NY: Macmillan Healthcare Information; 1987:153-163.
15. Moro E, Poon YY, Lozano AM, Saint-Cyr JA, Lang AE. Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol. 2006; 63(9):1266-1272. (Pubitemid 44379827)
16. Moro E, Esselink RJ, Benabid AL, Pollak P. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain. 2002;125(pt 11):2408-2417. (Pubitemid 35303501)
17. Moreau C, Defebvre L, Desteapose A, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology. 2008;71(2):80-84.
18. Brozova H, Barnaure I, Alterman RL, Tagliati M. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology. 2009;72(8):770.
19. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000;15(3):479- 484.
20. Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66(8):1200-1206. (Pubitemid 43739704)
21. Temperli P, Ghika J, Villemure JG, Burkhard PR, Bogousslavsky J, Vingerhoets FJ. How do parkinsonian signs return after discontinuation of subthalamic DBS? Neurology. 2003;60(1):78-81. (Pubitemid 36070648)
22. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-844.